Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Why Baxter’s GMP False Claims Settlement Was Smaller Than Those Of GSK, Ranbaxy

Jan 26 2017

• By Bowman Cox

Related Content

The Case of Baxter’s Moldy HEPA Filters

Jan 26 2017

GSK Paxil, Avandamet Seizure Will Have “Ripple Effect” On GMPs, FDAer Says

Mar 16 2005

FDA Seizure Of Paxil CR, Avandamet Follows GSK's Failure To Recall All Lots

Mar 04 2005

"Shock waves" from GSK's $750M settlement on alleged cGMP failures, lawyers say

Oct 29 2010

Ingredients For A Qui Tam Suit: GSK’s Cidra Plant Violations

Nov 01 2010

GMP Violations At GSK's Former Puerto Rico Plant Are Basis Of $750 Million DoJ Settlement

Oct 26 2010

Ranbaxy Woes Continue With 33-Product Import Alert

Sep 16 2008

U.S. FDA Issues Life Ban For 27 Ranbaxy Products, Company Says Move To Have “Negligible Commercial Impact”

Aug 22 2012

Ranbaxy’s $500 Million Settlement Includes Criminal Penalties

May 14 2013

Related Companies

Baxter International Inc.

GSK plc

Ranbaxy Laboratories Limited

Additional Topics

United States Quality Compliance Manufacturing BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window